BR112017017608A2 - métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia. - Google Patents
métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.Info
- Publication number
- BR112017017608A2 BR112017017608A2 BR112017017608A BR112017017608A BR112017017608A2 BR 112017017608 A2 BR112017017608 A2 BR 112017017608A2 BR 112017017608 A BR112017017608 A BR 112017017608A BR 112017017608 A BR112017017608 A BR 112017017608A BR 112017017608 A2 BR112017017608 A2 BR 112017017608A2
- Authority
- BR
- Brazil
- Prior art keywords
- schizophrenia
- iloperidone
- treating
- symptom
- maintain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
aspectos da invenção referem-se geralmente ao tratamento de esquizofrenia em um indivíduo e, mais especificamente, ao tratamento de um indivíduo com iloperidona, um metabolito de iloperidona, ou um sal farmaceuticamente aceitável do mesmo. em uma modalidade, a invenção provê um método de prevenção de recaída esquizofrênica em um indivíduo diagnosticado com esquizofrenia, o método compreendendo: administrar iloperidona ao indivíduo, um metabolito de iloperidona, ou um sal farmaceuticamente aceitável do mesmo em uma dose diária de entre cerca de 12 mg e cerca de 16 mg após um período no qual a esquizofrenia do indivíduo foi metabolizada.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562117173P | 2015-02-17 | 2015-02-17 | |
US201562172436P | 2015-06-08 | 2015-06-08 | |
PCT/US2016/018316 WO2016134049A1 (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017017608A2 true BR112017017608A2 (pt) | 2018-05-08 |
Family
ID=55532275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017017608A BR112017017608A2 (pt) | 2015-02-17 | 2016-02-17 | métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia. |
Country Status (10)
Country | Link |
---|---|
US (2) | US10441580B2 (pt) |
EP (1) | EP3258935B1 (pt) |
JP (1) | JP6885649B2 (pt) |
KR (1) | KR20170118830A (pt) |
CN (2) | CN116211857A (pt) |
BR (1) | BR112017017608A2 (pt) |
CA (1) | CA2976383C (pt) |
ES (1) | ES2870498T3 (pt) |
HK (1) | HK1248551A1 (pt) |
WO (1) | WO2016134049A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
WO2024137439A1 (en) * | 2022-12-19 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050020632A1 (en) | 2001-08-31 | 2005-01-27 | Dominique Grimler | Optical isomers of an iloperidone metabolite |
JP5067998B2 (ja) | 2001-10-30 | 2012-11-07 | ノバルティス アーゲー | イロペリドンおよび星形ポリマーのデポー製剤 |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
ES2825949T3 (es) * | 2004-09-30 | 2021-05-17 | Vanda Pharmaceuticals Inc | Métodos para administrar iloperidona |
US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
US9328387B2 (en) * | 2007-09-10 | 2016-05-03 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on SNP genotype |
US9439906B2 (en) * | 2007-12-19 | 2016-09-13 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
WO2010132866A1 (en) | 2009-05-15 | 2010-11-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
CN104220074A (zh) * | 2011-12-02 | 2014-12-17 | 大日本住友制药株式会社 | 鲁拉西酮新给药方案以及其用于治疗、预防和/或控制至少一种cns病症的用途 |
JP2015510893A (ja) | 2012-03-14 | 2015-04-13 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 精神障害の治療における使用のためのイロペリドン代謝物 |
RU2667010C2 (ru) * | 2012-08-21 | 2018-09-13 | Сейдж Терапьютикс, Инк. | Способы лечения эпилепсии или эпилептического статуса |
-
2016
- 2016-02-17 US US15/549,820 patent/US10441580B2/en active Active
- 2016-02-17 EP EP16710038.7A patent/EP3258935B1/en active Active
- 2016-02-17 WO PCT/US2016/018316 patent/WO2016134049A1/en active Application Filing
- 2016-02-17 JP JP2017543816A patent/JP6885649B2/ja active Active
- 2016-02-17 BR BR112017017608A patent/BR112017017608A2/pt not_active Application Discontinuation
- 2016-02-17 ES ES16710038T patent/ES2870498T3/es active Active
- 2016-02-17 CN CN202310398029.9A patent/CN116211857A/zh active Pending
- 2016-02-17 CN CN201680010479.4A patent/CN107249586A/zh active Pending
- 2016-02-17 CA CA2976383A patent/CA2976383C/en active Active
- 2016-02-17 KR KR1020177026225A patent/KR20170118830A/ko not_active Application Discontinuation
-
2018
- 2018-06-27 HK HK18108258.0A patent/HK1248551A1/zh unknown
-
2019
- 2019-09-06 US US16/562,548 patent/US10987346B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN116211857A (zh) | 2023-06-06 |
CA2976383C (en) | 2023-05-23 |
JP2018505901A (ja) | 2018-03-01 |
US20180021324A1 (en) | 2018-01-25 |
EP3258935B1 (en) | 2021-04-07 |
JP6885649B2 (ja) | 2021-06-16 |
CA2976383A1 (en) | 2016-08-25 |
EP3258935A1 (en) | 2017-12-27 |
WO2016134049A1 (en) | 2016-08-25 |
US10441580B2 (en) | 2019-10-15 |
US10987346B2 (en) | 2021-04-27 |
KR20170118830A (ko) | 2017-10-25 |
US20190388412A1 (en) | 2019-12-26 |
ES2870498T3 (es) | 2021-10-27 |
CN107249586A (zh) | 2017-10-13 |
HK1248551A1 (zh) | 2018-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018003984A2 (pt) | anticorpos | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112018008965A8 (pt) | terapia de reposição de plasminogênio para deficiência de plasminogênio | |
PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
MX2017000366A (es) | Terapia de combinacion para el cancer. | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
BR112017011642A2 (pt) | composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
BR112018009413A2 (pt) | formulação oral sólida e método para preparar a formulação oral sólida | |
BR112017017608A2 (pt) | métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia. | |
BR112013018781A2 (pt) | composto derivado de piridona, e, composição farmacêutica | |
BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . | |
BR112015012497A2 (pt) | combinações farmacêuticas | |
BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |